Abstract: A method of registering the position of an object moving in a target volume in an ultrasound imaging system includes capturing a first ultrasound image of a target volume. A second ultrasound image of the target volume is then captured after the capturing of the first ultrasound image. The position of the object in the target volume is identified using differences detected between the first and second ultrasound images. In another aspect, a region of interest in the target volume is determined. A segment of an operational scan range of a transducer of the ultrasound imaging system encompassing the region of interest is determined. The transducer is focused on the segment of the operational scan range during image capture.

Abstract: A mechanical arm assembly comprises an arm rotatable about a pivot, a first force generating device for maintaining the arm at a datum, and a second force generating device for compensating for the first generating device to maintain the arm in positions other than the datum.

Abstract: A method of treating a pathophysiological condition caused by the production of growth-inhibiting proteoglycans is provided. It is based on the finding that down-regulation of SOX9 results in decreased production of growth-inhibiting factors such as proteoglycans, and increased production of growth-promoting factors such as a laminin and fibronectin. The method of the present invention comprises the inhibition of SOX9 expression and function with an inhibitor such as an antisense oligonucleotide or a siRNA.

Abstract: A system and method for performing a biopsy of a target volume and a computing device for planning the same are provided. A three-dimensional ultrasound transducer captures ultrasound volume data from the target volume. A three-dimensional registration module registers the ultrasound volume data with supplementary volume data related to the target volume. A biopsy planning module processes the ultrasound volume data and the supplementary volume data in combination in order to develop a biopsy plan for the target volume. A biopsy needle biopsies the target volume in accordance with the biopsy plan.

Abstract: Myxoma viruses that are deficient in the activity of a Myxoma virus protein selected from the group consisting of M11L, M063, M 136, M-T4 and M-T7 are useful for treating cancer.

Abstract: An apparatus for determining a distribution of a selected therapy in a target volume is provided. A three-dimensional ultrasound transducer captures volume data from the target volume. A computing device is in communication with the three-dimensional ultrasound transducer for receiving the volume data and determining the distribution of the selected therapy in the target volume along a set of planned needle trajectories using the volume data. At least one of the needle trajectories is oblique to at least one other of the planned needle trajectories.

Abstract: Methods are provided for increasing stem cells, hematopoietic progenitor/stem cells, mesenchymal progenitor/stem cells, mesodermal progenitor/stem cells, muscle progenitor/stem cells, or neural progenitor/stem cells in vivo in a mammalian subject. Methods are also provided for treating an immune related disease, a mesenchymal/mesoderm degenerative disease, or a neurodegenerative disease in a mammalian subject in need thereof.

Abstract: The present invention relates to therapeutic use of Myxoma virus. Myxomas virus can selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon and can be used to treat diseases characterized by the presence of such cells, including cancer.

Abstract: A surface coil array comprises a surface coil support and an arrangement of non-overlapping magnetically decoupled surface coils mounted on the support. The surface coils encompass a volume into which a target to be imaged is placed. Magnetic decoupling circuits act between adjacent surface coils. Impedance matching circuitry couples the surface coils to conventional transmit and receive components.

Abstract: The present invention relates to therapeutic use of Myxoma virus. Myxoma virus can selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon and can be used to treat diseases characterized by the presence of such cells, including cancer.

Abstract: Methods and compositions for treating hyperglycemia and pancreatic damage as well as stimulating the repair or regeneration of islet cells are disclosed.

Abstract: This disclosure provides a system for minimizing the alloreactivity of tissue transplants. The patient is administered with undifferentiated embryonic stem cells or early progenitor cells. This induces a state of inflammatory quiescence or immune unresponsiveness, which in turn enhances engraftment of cells derived from the same stem cell line given for purposes of regenerative medicine.

Abstract: A method for determining tissue type includes quantitatively determining a tissue blood flow (TBF) by deconvoluting Q(t) and Ca(t), where Q(t) represents a curve of specific mass of contrast, and Ca(t) represents an arterial curve of contrast concentration, and quantitatively determining a tissue blood volume (TBV) by deconvoluting Q(t) and Ca(t). The method also includes quantitatively determining a tissue mean transit time (TMTT) by deconvoluting Q(t) and Ca(t), and quantitatively determining a tissue capillary permeability surface area product (TPS) by deconvoluting Q(t) and Ca(t). The method also includes determining a tissue type based on the TBF, the TBV, the TMTT, and the TPS.

Abstract: This invention provides a system for producing cells of the hematopoietic lineage from embryonic stem cells. Differentiation is conducted in the presence of hematogenic cytokines and other factors listed in the disclosure. The cell population that is obtained is remarkably enriched in CD45 +ve cells, a marker of early hematopoietic precursor with self-renewing capacity. Including a bone morphogenic protein during the differentiation process enhances the ability of the cell population to form secondary colonies. Because of the enormous replicative capacity of embryonic stem cells, this provides an important new commercial source of hematopoietic cells.

Abstract: This invention provides a system for producing cells of the hematopoietic lineage from embryonic stem cells. Differentiation is conducted in the presence of hematogenic cytokines and other factors listed in the disclosure. The cell population that is obtained is remarkably enriched in CD45 +ve cells, a marker of early hematopoietic precursor with self-renewing capacity. Including a bone morphogenic protein during the differentiation process enhances the ability of the cell population to form secondary colonies. Because of the enormous replicative capacity of embryonic stem cells, this provides an important new commercial source of hematopoietic cells.

Abstract: This invention provides a system for producing cells of the hematopoietic lineage from embryonic stem cells. Differentiation is conducted in the presence of hematogenic cytokines and other factors listed in the disclosure. The cell population that is obtained is remarkably enriched in CD45 +ve cells, a marker of early hematopoietic precursor with self-renewing capacity. Including a bone morphogenic protein during the differentiation process enhances the ability of the cell population to form secondary colonies. Because of the enormous replicative capacity of embryonic stem cells, this provides an important new commercial source of hematopoietic cells.